Navigation Links
Cardiovascular fitness not affected by cancer treatment

Washington, DC The cardiovascular fitness level of cancer survivors is not affected by many standard cancer therapies, say researchers from Georgetown University Medical Cancer. That is the finding of a new observational study to be presented today at the American College of Sports Medicine in Seattle.

"We know physical activity is a critical component of cancer survivorship, both during and after cancer treatment," says Jennifer LeMoine, PhD, a post-doctoral research fellow with training in exercise physiology at GUMC's Lombardi Comprehensive Cancer Center. "In order to prescribe an exercise program, it's critical that we understand our patient's fitness level and whether or not treatment has had an impact on their cardiovascular health."

For the study, the researchers conducted a chart review of 49 women who attended a physician-directed fitness clinic for cancer survivors, founded and run by Priscilla Furth, MD, the study's co-author. The data included demographics, physical activity levels and cancer treatment type, duration and time since their treatment. Fitness assessments were conducted using a three-minute step test during a clinic visit. The purpose of the study was to access the step test as a way of determining a patient's current cardiovascular fitness level.

LeMoine says, "Often, what people think they are physically capable of doing and what they can actually do are two very different things. Many have a better fitness level than they expect while some find they're not as fit as they thought. The step-test gives us a better idea of their exercise tolerance and cardiovascular-fitness."

All the patients in the study were women and were diverse by age and body mass index. Their cancer diagnoses and treatments varied. Overall, 33 percent of the survivors were sedentary and 67 percent reported being physically active. Thirty-five (71 percent) of the participants completed the step test. Test completion and heart rate recovery were not affected by treatment, BMI, or age.

"What's really exciting to us was that we found that cardiovascular fitness was not affected by the expected culprits -- cancer treatment, type, duration or time since treatment," LeMoine explains. "That isn't to say there aren't side-effects of some treatments that may hinder physical activity, but when it comes to actual cardiovascular fitness as measured in our clinic, many of the standard treatments didn't have a role."

"We've modified an in-clinic cardiovascular assessment tool , the three-minute step test, with the goal of finding a test that can easily and quickly be performed in a physician's office," explains Priscilla A. Furth, MD, a professor of oncology and medicine at Lombardi. "Having this kind of evaluation tool is critical for physicians, like me, who are interested in prescribing physical activity for this population."


Contact: Karen Mallet
Georgetown University Medical Center

Related medicine news :

1. Health and Advocacy Leaders Mobilize to Bring Attention to Atrial Fibrillation, a Costly and Misunderstood Cardiovascular Disease
2. Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events
3. The cardiovascular benefits of daily exercise in school children are evident even after 1 year
4. 30-year follow-up study: Tremendous impact of smoking on mortality and cardiovascular disease
5. More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure
6. The cardiovascular benefits of daily exercise in school children are evident even after one year
7. New Research Demonstrates that Wild Blueberries May Support Cardiovascular Health
8. MedAptus Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice
9. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
10. CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y.
11. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology: